Fresh Tracks Therapeutics improves revenue, decreases loss during ‘transformational’ quarter
BOULDER — Fresh Tracks Therapeutics Inc. (Nasdaq: FRTX), the Boulder-based pharmaceutical company formerly called Brickell Biotech, saw both its top and bottom lines improve in the third quarter of 2022, a key transitional period for the company.
Revenue was $500,000 for the third quarter of 2022, compared with $100,000 for the third quarter last year.
Fresh Tracks’ net loss was $6 million for the most recent period, an improvement on a net loss of $13.3 million in the third quarter of 2021.
The company’s September rebrand occurred as the company seeks to pivot away from drugs that combat excessive sweating toward treatments…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
Medical-device firm Boulder iQ has nearly doubled its Boulder footprint with the purchase of a…
-
Edgewise Therapeutics Inc., a Boulder-based muscle disease biopharmaceutical company, increased its research and development spending…
-
OnKure Inc., a Boulder precision oncology company, and California-based Reneo Pharmaceuticals Inc. have completed a…
-
Mosaic Biosciences Inc., a Boulder drug-discovery company that provides protein and antibody therapeutics research to…
